Search
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. … it reaches the small intestine.
Synonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acidProducts: MICOFENOLATO DE MOFETILO, MICOFENOLATO DE MOFETILO CAPSULAS 250 MGThimerosal
go.drugbank.com/drugs/DB11590ApprovedAlthough thimerosal is banned in several countries, it continues to be included as a preservative in some vaccines in the United States and many vaccines in the developing world [L1685]. … There has been significant concern regarding its safety and toxicity in the last several decades.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalMutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung.
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.
Netupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. … Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy
Categories: Substance P/Neurokinin-1 Receptor AntagonistTaletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigationalthe secondary solvent-front mutation _G2032R_ is 400-times lower than that of the previously approved first-generation inhibitors [crizotinib] and [entrectinib]. … [A274158] As part of the second-generation of ROS1 inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting
Perflubutane
go.drugbank.com/drugs/DB12821ApprovedInvestigationalWithdrawnIt is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease. … Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease.
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Pancrelipase protease
go.drugbank.com/drugs/DB11066ApprovedInvestigational[L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … [A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]
Mianserin
go.drugbank.com/drugs/DB06148ApprovedWithdrawnA tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of mirtazapine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Antagonists